Cargando…
31.4 GENETIC, IMMUNOLOGICAL AND BIOCHEMICAL MARKERS OF TREATMENT RESPONSE IN SCHIZOPHRENIA
BACKGROUND: One of the major shortcomings in the current treatment of schizophrenia is that we have no valid criteria in clinical practice to decide which antipsychotic treatment should be chosen first. This is why we need to define a blood-based biological signature of treatment response that can b...
Autores principales: | Leboyer, Marion, Jamain, Stephane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888528/ http://dx.doi.org/10.1093/schbul/sby014.130 |
Ejemplares similares
-
Performance of the CERN ISR at 31.4 GeV
por: Fischer, C, et al.
Publicado: (1979) -
Ring 2 Working Line Curvative during Acceleration to 31.4 GeV, Run 1305, 31.4 GeV, Ring 2
por: Poole, J, et al.
Publicado: (1982) -
Run 468 - 23 May 1974, Rings 1 and 2 - 26.57 to 31.4 GeV/c with SFM: Acceleration to 31.4 GeV/c
por: De Jonge, M J, et al.
Publicado: (1974) -
31.4 PROJECT REACH: REDEFINING FAMILY SUPPORT IN THE CONTEXT OF THE COVID-19 PANDEMIC
por: Kistin, Caroline, et al.
Publicado: (2021) -
31. OPTIMISE-ING THE TREATMENT OF FIRST-EPISODE SCHIZOPHRENIA
por: Arango, Celso
Publicado: (2018)